Lazcluze (Lazertinib Mesylate) Patent Expiration, LOE Window & CMS Spending

Lazcluze (Lazertinib Mesylate) by Johnson & Johnson: FDA Orange Book core substance LOE 2038-04-18 (last listed 2041-08-01), 0 AB generics, $7.8M 2024 CMS Part D & Medicaid spend, and $18,198 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorJohnson & Johnson
FDA Application & PathwayN219008 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2038-04-18
Last Listed Patent or Exclusivity Date2041-08-01
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$7.8M
2024 Medicare Part D Spend$7.1M
2024 Medicaid Spend$661K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($18,198 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.